Influence of HLA-DRB1 alleles and HBV genotypes on interferon-α therapy for chronic hepatitis B

Table 1 Distribution of HLA-DRB1*03,*07,*09,*12,*15 alleles in patients with chronic hepatitis B and healthy controls

DRB1*Allele	Chronic hepatitis (n = 126)		Normal control (n = 76)		RR	χ2	P
	PN	PR (%)	PN	PR (%)
0301/0302	10	7.9	5	6.6	1.24	0.13	> 0.75
0701/0702	46	36.5	15	19.7	2.37	6.33	< 0.025
901	31	24.6	22	28.9	0.8	0.46	> 0.50
1201/1202	17	13.5	12	15.8	0.85	0.2	> 0.75
1501/1502	16	12.7	9	11.8	1.08	0.03	> 0.90
Blank	19	15	8	10.5	1.51	0.85	> 0.50

PN: positive number, PR: positive rate, RR: relative risk.

Table 2 Prevalence of different HBV genotypes in patients with chronic hepatitis B

Genotype	Number	%
B	38	30.2
C	69	54.8
B+C	19	15
D	0	0
E	0	0
F	0	0

Table 3 Correlation between DRB1*07 and IFN-α therapy, n (%)

	Responder(n = 33)	Non-responder(n = 93)	Total(126)	χ2	P
HLA-DRB1*07(+)	7 (15.2)	39 (84.8)	46	4.51	< 0.05
HLA-DRB1*07(-)	26 (32.5)	54 (67.5)	80

Table 4 Response to interferon-α therapy in patients with different genotypes, n (%)

	Responder	Non-responder	Total	χ2	P
Genotype				17.3	< 0.005
B	19 (50)	19 (50)	38
C	9 (13)	60 (87)	69
B+C	5 (26.3)	14 (73.7)	19

Table 5 Response to interferon-α therapy in patients with HLA-DRB1*07 and genotype C, n (%)

		Responder	Non-responder	Total	χ2	P
HLA-DRB1*07+
genotype C					6.36	< 0.05
+	+	2 (7.7)	24 (92.3)	26
+	-	7 (35)	13 (65)	20
-	+	14 (32.6)	29 (67.4)	43